Puma Biotech (PBYI) Tops Q4 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.43, $0.32 better than the analyst estimate of $0.11. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $55.45 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Enact Holdings (ACT) Reports In-Line Q3 EPS
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
